There are now several studies indicating that vitamin D status affects selected clinical endpoints in MS, but evidence for treatment benefits has been mixed.
Latest News
Levetiracetam in newly-diagnosed epilepsy: KOMET trial results
February 27, 2013Levetiracetam does not show superiority over standard agents for patients newly-diagnosed with epilepsy, according to the results of the KOMET trial.
Gait dysfunction in AD: clinical and anatomical correlates
February 27, 2013A cross-sectional study in Spain has examined clinical correlates of gait dysfunction in AD patients, with further analyses using volumetric MRI and diffusion tensor imaging (Olazaran et al. J Alzheimers Dis 2013;33:495-505).
Pilot study of GSK-3 drug tested in AD
February 13, 2013A pilot phase IIa study (NCT00948259) has reported promising effects of tideglusib, a novel inhibitor of glycogen synthase-3 (GSK-3), in 30 patients with mild to moderate Alzheimer’s disease (Del Ser et al. J Alzheimers Dis 2013;33:205-215).